SOPHiA GENETICS and AstraZeneca Spain Commit to Increasing Ovarian Cancer Testing in Spain

SOPHiA GENETICS and AstraZeneca Spain expand HRD testing program to support molecular diagnosis of ovarian cancer in Spain.

← Previous
Next →
  • HEALTH / LIFESTYLE
  • ARTICLES OF INTEREST
  • ABOUT
    • EDITORIAL
    • SUBMIT PRESS RELEASES
  • ADVERTISE
  • CONTACT
  • PRIVACY
    • COOKIE POLICY
  • HEALTH / LIFESTYLE
  • ARTICLES OF INTEREST
  • ABOUT
    • EDITORIAL
    • SUBMIT PRESS RELEASES
  • ADVERTISE
  • CONTACT
  • PRIVACY
    • COOKIE POLICY

© 2026 All rights Reserved. Medical Device News Magazine, is a Division of PTM Healthcare Marketing, Inc.